Research and Markets has announced the addition of the "In Vitro Diagnostics (IVD) Quality Control Product Market by Product Type, by Application, by End User, by Manufacturer Type - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering.

The global IVD quality control products market was valued at $823 million in 2015, and is expected to reach $1,052 million by 2022, registering a CAGR of 3.5% from 2016 to 2022.

The market is driven by factors such as increase in adoption of third party quality control products, upsurge in the number of laboratories and diagnostic centers worldwide, and stringent norms for using controls. However, poor reimbursement framework and lack of regulations on the use of controls in the emerging economies are projected to hamper the market growth during the analysis period.

The global IVD quality controls products market is segmented based on product type into quality controls, IVD quality control data management software, and IVD quality assurance services. In 2015, the quality controls segment accounted for the largest share in the global market, and is estimated to grow at the fastest CAGR of 3.7% during the analysis period. The market growth is attributed to upsurge in demand for third-party quality control products and services.

The IVD quality controls market is segmented based on application into clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation, microbiology, and others. The molecular biology diagnostics segment is estimated to grow at the fastest CAGR of 5.3% during the analysis period. The end users of the market are hospitals, clinical laboratories, research & academic institutes, and others. The hospitals segment held the largest share in the global IVD quality control products market in 2015.

Based on manufacturer type, the market is segment into instrument manufacturer controls and independent manufacturer controls including third party controls and instrument specific controls. The independent manufacturer controls segment dominated the market in 2015, and is estimated to grow at the fastest CAGR during the forecast period, owing to the increase in demand for third party controls.

Companies Mentioned

  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Randox Laboratories Ltd.
  • Roche Diagnostics
  • Abbott Diagnostics
  • Helena Laboratories
  • Seracare Life Sciences, Inc.
  • Technopath Clinical Diagnostics
  • Sun Diagnostics, LLC.

For more information about this report visit http://www.researchandmarkets.com/research/dw9654/in_vitro